Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver.
The post Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition appeared first on MedCity News.
IRISSCON 2025 to address the human impact on cybersecurity
Recent high-profile cybersecurity breaches affecting global brands share a common link: the human factor. Expert speakers will cover this subject in depth at IRISSCON 2025,
